Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
In-depth stories
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
Poster selection
icml lugano 2025 poster 1
May 11, 2025
Dr Victoria Bordon discussed the results of a qualitative study that explored the lived experiences and relational significance of minor sibling donors to enhance psychosocial care and address their unique
eha milan 2025 poster 1
May 11, 2025
Dr Victoria Bordon discussed the results of a qualitative study that explored the lived experiences and relational significance of minor sibling donors to enhance psychosocial care and address their unique
healing bonds
April 10, 2025
Dr Victoria Bordon discussed the results of a qualitative study that explored the lived experiences and relational significance of minor sibling donors to enhance psychosocial care and address their unique
Hemorrhagic cystitis
April 8, 2025
Dr Pauline Mazilier conducted a retrospective study to analyze the characteristics and treatments received by pediatric patients who developed HC following a HSCT.
Promising efficacy and a low rate of cytokine release syndrome with ABBV-383 in patients with released/refractory multiple myeloma
December 26, 2024
Dr Muhamed Baljevic is a haematologist at the Vanderbilt University Medical Center, in Nashville, Tennessee (USA). In this vide, he discusses the results of a phase 1b study evaluating different
Patient-reported outcomes for Hemophilia A patients treated with Mim8
December 26, 2024
Prof Cédric Hermans is the head of the haematology department at the Cliniques Universitaires St.-Luc in Brussels (Belgium). During ASH 2024 he presented the patient-reported outcomes for patients treated with
CD19 expression is maintained after treatment with tafasitamab in patients with DLBCL
December 26, 2024
During ASH 2024, Dr Johannes Duell from the University of Würzburg (Germany) presented a poster evaluating the CD19 expression before and after treatment with tafasitamab-lenalidomide in patients with relapsed/refractory diffuse
Tafasitamab-lenalidomide for relapsed/refractory DLBCL: real-world data from the United States
December 26, 2024
During ASH 2024, Dr Kim Saverno from the Incyte Corporation (Wilmington, DE, USA) presented real-life data with tafa-len in a cohort of 181 R/R DLBCL patients treated with this regimen